中国生物制药旗下纳洛酮类药物Naldemedine获准在粤港澳大湾区提前上市

美股速递
Apr 09

中国生物制药近日宣布,其创新药物Naldemedine已获得监管批准,将在粤港澳大湾区提前上市销售。这一进展标志着公司在疼痛管理领域取得重要突破,也为大湾区患者提供了新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10